NDAORALTABLET
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
PROPECIA (finasteride) by Merck & Co. is 5-alpha reductase inhibitors [moa]. First approved in 1997.
Drug data last refreshed 2d ago
Mechanism of Action
5-alpha Reductase Inhibitors
Pharmacologic Class:
5-alpha Reductase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Started Aug 2013
1 enrolled
Benign Prostatic Hyperplasia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
Started Oct 2010
917 enrolled
Androgenetic Alopecia
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
Started Sep 2010
696 enrolled
Benign Prostatic HyperplasiaEnlarged Prostate
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
Started Mar 2008
29 enrolled
HematuriaHematospermia
On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)
Started Feb 2008
0Benign Prostatic Hyperplasia
Worked on PROPECIA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.